Similarly, the pivotal role that HGF seems to play in cancer has led to the preclinical development of many types of targeting drugs, including antagonists, which compete with binding to the receptor, antibodies, which block the receptor, small-compound tyrosin kinase inhibitors, or other strategies that target downstream signals or secondary gene expression (Jiang et al, 2005). This evidence concerns the gene HGF and cancer.